Remibrutinib for chronic spontaneous urticaria
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This program offers remibrutinib, an experimental oral medication, to adults with chronic spontaneous urticaria (long-lasting hives without a known trigger) that hasn't improved with standard antihistamines or omalizumab. It aims to see if this drug can reduce symptoms when other options haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had chronic spontaneous urticaria (hives without a clear trigger) for at least 6 months.
- Your hives have not improved with antihistamines or omalizumab (if you've tried it).
- You are not able to join a clinical trial, or no trials are available to you.
- You are not pregnant, breastfeeding, or planning to become pregnant during the treatment.
- You do not have other conditions that cause hives or itching, like a specific trigger or skin disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan using remibrutinib (a pill) and omalizumab (a biologic shot) for adults with chronic spontaneous urticaria (chronic hives) that are not well controlled by antihistamines. The goal is to see if this combination can reduce itching and hives better than current options.
This study observes how well remibrutinib works for people with chronic hives (CSU) in everyday medical practice. It compares three groups based on treatments you have tried, and checks if switching to remibrutinib helps control symptoms.
This study follows people with chronic hives (CSU) who start taking remibrutinib as part of their normal care. It looks at how well the medicine works in real life over 24 months.
This study follows people with chronic spontaneous urticaria (long-lasting hives with no clear cause) who are starting a new medicine called remibrutinib or dupilumab. It aims to see how well these treatments work in everyday life.
This study observes how remibrutinib (a newer medication) works for chronic hives (CSU) when prescribed in routine clinical practice in Germany. Remibrutinib is used when standard allergy medications don't work well enough. The study tracks your symptoms and treatment over 24 months to understand how well it helps real patients.
This trial tests a new oral medication called tacabrutideg (BGB-16673) for chronic spontaneous urticaria, a condition with frequent hives and itching. It aims to see how safe it is and how well it works, possibly offering a new option for people who still have symptoms despite antihistamines.
Hear when a new Chronic Spontaneous Urticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.